≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Other and unspecified postprocedural disorders of eye and adnexa

DOID EFO Endpoint Browser PheWeb

H7_POSTOPEYENAS

eye disease: A non-neoplastic or neoplastic disorder that affects the eye. Representative examples include conjunctivitis, glaucoma, cataract, conjunctival squamous cell carcinoma, uveal melanoma, and retinoblastoma. [NCIt:C26767]

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

2 out of 7 registries used, show all original rules.

93

4. Check minimum number of events

None

93

5. Include endpoints

None

93

6. Filter based on genotype QC (FinnGen only)

86

Control definitions (FinnGen only)

Control exclude
H7_EYEPOSTOP

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 541 282 257
Only index persons 456 238 218
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.01
Only index persons 0.01 0.01 0.01
Median age at first event (years)
Whole population 71.21 72.30 70.00
Only index persons 69.97 70.56 69.33

-FinnGen-

Key figures

All Female Male
Number of individuals 86 46 40
Unadjusted period prevalence (%) 0.02 0.02 0.02
Median age at first event (years) 72.95 73.92 71.83

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
93
Matched controls
930
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H59.9
ICD-10 Finland
Postprocedural disorder of eye and adnexa, unspecified
1027.1
57.0
50
*
H59.8
ICD-10 Finland
Other postprocedural disorders of eye and adnexa
+∞
49.5
43
*
WX140
NOMESCO Finland
Parabulbar anesthesy
20.3
39.8
36
28
Z96.1
ICD-10 Finland
Presence of intraocular lens
11.2
31.7
58
120
WX100
NOMESCO Finland
Conjunctival surface anesthesia
8.9
25.5
49
103
CJE99
NOMESCO Finland
Other extracapsular cataract operation using phakoemulsification technique
+∞
19.4
18
*
S01ED51
ATC
timolol, combinations; ophthalmic
8.3
18.9
31
53
CKD60
NOMESCO Finland
Anterior vitrectomy
44.5
17.6
21
6
CKD94
NOMESCO Finland
Combined vitrectomy and procedure on lens through pars plana
33.3
16.5
21
8
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
7.9
14.5
23
37
CJF10
NOMESCO Finland
Secondary implantation of artificial lens in posterior chamber
+∞
13.9
13
*
CHB10
NOMESCO Finland
Puncture of anterior chamber of eye with irrigation
29.2
13.0
17
7
CJW99
NOMESCO Finland
Other operation on lens
149.3
12.8
13
*
H25.8
ICD-10 Finland
Other senile cataract
5.0
11.8
34
96
CJE20
NOMESCO Finland
Phakoemulsification with implantation of artificial lens in posterior chamber
4.9
11.6
67
321
H33.0
ICD-10 Finland
Retinal detachment with retinal break
12.8
10.3
18
17
S01CA01
ATC
dexamethasone and antiinfectives; ophthalmic
4.0
9.7
58
274
CKD40
NOMESCO Finland
Endophotocoagulation of retina
22.6
8.7
12
6
T85.2
ICD-10 Finland
Mechanical complication of intraocular lens
+∞
8.5
8
*
CKD20
NOMESCO Finland
Removal of vitreous body substitute
49.3
7.9
9
*
S01EE01
ATC
latanoprost; ophthalmic
4.9
7.7
19
46
H27.0
ICD-10 Finland
Aphakia
86.7
7.5
8
*
CKD65
NOMESCO Finland
Pars plana or pars plicata vitrectomy
10.6
7.1
13
14
CKD10
NOMESCO Finland
Insufflation of vitreous cavity
13.6
6.8
11
9
CKD92
NOMESCO Finland
Combined vitrectomy and retinal procedure
15.8
6.6
10
7
CKD15
NOMESCO Finland
Injection of vitreous substitute
74.8
6.5
7
*

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Ophthalmology
18 [38004463]
8.7e-01
2.1e+00
3.3e+00
1.0e+50
4.5e+00
2.7e+00
1.5e+00
cases:46.24%
controls:26.45%
cases:52.69%
controls:12.26%
cases:43.01%
controls:2.69%
cases:84.95%
controls:0.00%
cases:65.59%
controls:2.06%
cases:68.24%
controls:12.47%
cases:57.63%
controls:22.88%
43
246
50
684
49
114
44
816
40
25
53
905
79
0
14
930
61
19
32
905
58
103
27
723
34
124
25
418
Outpatient Visit
OP [9202]
3.4e-01
8.2e-01
1.2e+00
4.8e+00
1.3e+00
7.6e-01
5.1e-01
cases:87.10%
controls:82.80%
cases:80.65%
controls:64.62%
cases:27.96%
controls:10.75%
cases:48.39%
controls:0.75%
cases:31.18%
controls:11.15%
cases:75.29%
controls:58.84%
cases:88.14%
controls:81.73%
81
770
12
160
75
601
18
329
26
100
67
830
45
7
48
923
29
103
64
821
64
486
21
340
52
443
7
99
Presence of intraocular lens
Z96.1 [45585885]
6.6e-01
1.6e+00
—
1.0e+50
—
3.5e+00
1.8e+00
cases:8.60%
controls:4.62%
cases:9.68%
controls:2.04%
—
—
cases:11.83%
controls:0.00%
—
—
cases:38.82%
controls:1.82%
cases:22.03%
controls:4.24%
8
43
85
887
9
19
84
911
—
11
0
82
930
—
33
15
52
811
13
23
46
519
hypromellose
S01KA02 [21605115]
1.1e+00
1.8e+00
—
—
—
2.0e+00
2.1e+00
cases:11.83%
controls:4.09%
cases:7.53%
controls:1.29%
—
—
—
—
—
—
cases:8.24%
controls:1.21%
cases:13.56%
controls:1.85%
11
38
82
892
7
12
86
918
—
—
—
7
10
78
816
8
10
51
532
timolol, combinations
S01ED51 [21603705]
1.4e+00
1.4e+00
-1.0e+50
—
2.9e+00
9.8e-01
1.3e+00
cases:13.98%
controls:3.76%
cases:11.83%
controls:3.12%
cases:0.00%
controls:0.97%
—
—
cases:13.98%
controls:0.87%
cases:9.41%
controls:3.75%
cases:11.86%
controls:3.51%
13
35
80
895
11
29
82
901
0
9
93
921
—
13
8
80
916
8
31
77
795
7
19
52
523
dexamethasone
S01BA01 [21603618]
6.6e-01
2.3e+00
—
—
—
3.0e+00
1.4e+00
cases:8.60%
controls:4.62%
cases:16.13%
controls:1.94%
—
—
—
—
—
—
cases:24.71%
controls:1.57%
cases:16.95%
controls:4.80%
8
43
85
887
15
18
78
912
—
—
—
21
13
64
813
10
26
49
516
dexamethasone
S03BA01 [21605201]
6.6e-01
2.3e+00
—
—
—
3.0e+00
1.4e+00
cases:8.60%
controls:4.62%
cases:16.13%
controls:1.94%
—
—
—
—
—
—
cases:24.71%
controls:1.57%
cases:16.95%
controls:4.80%
8
43
85
887
15
18
78
912
—
—
—
21
13
64
813
10
26
49
516
nepafenac
S01BC10 [21603648]
—
2.0e+00
1.0e+50
1.0e+50
—
3.2e+00
1.5e+00
—
—
cases:8.60%
controls:1.29%
cases:12.90%
controls:0.00%
cases:7.53%
controls:0.00%
—
—
cases:21.18%
controls:1.09%
cases:10.17%
controls:2.40%
—
8
12
85
918
12
0
81
930
7
0
86
930
—
18
9
67
817
6
13
53
529
Conjunctival surface anesthesia
WX100 [2001310764]
8.0e-01
2.9e+00
1.0e+50
1.0e+50
—
2.3e+00
—
cases:6.45%
controls:3.01%
cases:16.13%
controls:1.08%
cases:10.75%
controls:0.00%
cases:23.66%
controls:0.00%
—
—
cases:11.76%
controls:1.33%
—
—
6
28
87
902
15
10
78
920
10
0
83
930
22
0
71
930
—
10
11
75
815
—
Other senile cataract
H25.8 [45605644]
6.8e-01
2.2e+00
—
1.0e+50
—
2.9e+00
—
cases:5.38%
controls:2.80%
cases:8.60%
controls:1.08%
—
—
cases:22.58%
controls:0.00%
—
—
cases:18.82%
controls:1.21%
—
—
5
26
88
904
8
10
85
920
—
21
0
72
930
—
16
10
69
816
—
Senile nuclear cataract
H25.1 [45581628]
4.2e-02
1.8e+00
3.2e+00
—
—
1.3e+00
—
cases:8.60%
controls:8.28%
cases:16.13%
controls:3.12%
cases:11.83%
controls:0.54%
—
—
—
—
cases:10.59%
controls:3.15%
—
—
8
77
85
853
15
29
78
901
11
5
82
925
—
—
9
26
76
800
—
Case Management Agency
251B00000X [38004193]
7.8e-02
2.7e-01
5.9e-01
3.7e+00
8.2e-01
2.3e-01
-2.2e-01
cases:79.57%
controls:78.28%
cases:79.57%
controls:74.84%
cases:49.46%
controls:35.16%
cases:52.69%
controls:2.69%
cases:53.76%
controls:33.77%
cases:77.65%
controls:73.49%
cases:76.27%
controls:80.07%
74
728
19
202
74
696
19
234
46
327
47
603
49
25
44
905
50
312
43
612
66
607
19
219
45
434
14
108
Pharmacy visit
OMOP4822462 [581458]
1.0e+50
1.3e+00
1.1e+00
2.1e+00
1.2e+00
2.1e+00
8.5e-01
cases:100.00%
controls:97.20%
cases:97.85%
controls:92.47%
cases:81.72%
controls:60.22%
cases:24.73%
controls:3.76%
cases:84.95%
controls:61.80%
cases:98.82%
controls:91.04%
cases:98.31%
controls:96.13%
93
904
0
26
91
860
2
70
76
560
17
370
23
35
70
895
79
571
14
353
84
752
1
74
58
521
1
21
levofloxacin
S01AE05 [43534860]
3.4e-01
2.1e+00
—
1.0e+50
—
2.3e+00
1.2e+00
cases:7.53%
controls:5.48%
cases:12.90%
controls:1.72%
—
—
cases:7.53%
controls:0.00%
—
—
cases:12.94%
controls:1.45%
cases:10.17%
controls:3.14%
7
51
86
879
12
16
81
914
—
7
0
86
930
—
11
12
74
814
6
17
53
525
Emergency Room Visit
ER [9203]
2.8e-01
2.2e-01
2.0e+00
—
2.0e+00
4.8e-01
6.9e-01
cases:40.86%
controls:34.19%
cases:13.98%
controls:11.51%
cases:7.53%
controls:1.08%
—
—
cases:7.53%
controls:1.08%
cases:17.65%
controls:11.74%
cases:47.46%
controls:31.18%
38
318
55
612
13
107
80
823
7
10
86
920
—
7
10
86
914
15
97
70
729
28
169
31
373
Phakoemulsification with implantation of artificial lens in posterior chamber
CJE20 [2001301342]
-7.9e-02
1.9e+00
1.0e+50
1.0e+50
—
2.0e+00
4.2e-01
cases:8.60%
controls:9.25%
cases:13.98%
controls:2.47%
cases:10.75%
controls:0.00%
cases:10.75%
controls:0.00%
—
—
cases:16.47%
controls:2.54%
cases:8.47%
controls:5.72%
8
86
85
844
13
23
80
907
10
0
83
930
10
0
83
930
—
14
21
71
805
5
31
54
511
antibiotics in combination with other drugs
S01AA20 [21603571]
5.5e-01
2.0e+00
—
1.0e+50
—
1.4e+00
8.4e-01
cases:19.35%
controls:12.15%
cases:22.58%
controls:3.87%
—
—
cases:8.60%
controls:0.00%
—
—
cases:15.29%
controls:4.12%
cases:18.64%
controls:9.04%
18
113
75
817
21
36
72
894
—
8
0
85
930
—
13
34
72
792
11
49
48
493
combinations of corticosteroids
D07AB30 [21602118]
-5.3e-01
7.3e-01
—
—
3.1e+00
1.8e-01
6.9e-01
cases:8.60%
controls:13.76%
cases:10.75%
controls:5.48%
—
—
—
—
cases:12.90%
controls:0.65%
cases:5.88%
controls:4.96%
cases:22.03%
controls:12.36%
8
128
85
802
10
51
83
879
—
—
12
6
81
918
5
41
80
785
13
67
46
475
combinations of corticosteroids
D07XB30 [21602188]
-5.3e-01
7.3e-01
—
—
3.1e+00
1.8e-01
6.9e-01
cases:8.60%
controls:13.76%
cases:10.75%
controls:5.48%
—
—
—
—
cases:12.90%
controls:0.65%
cases:5.88%
controls:4.96%
cases:22.03%
controls:12.36%
8
128
85
802
10
51
83
879
—
—
12
6
81
918
5
41
80
785
13
67
46
475
Supplier / Service Provider
OMOP5117446 [33004]
-1.9e-01
9.3e-02
-1.0e+50
—
—
—
2.6e+00
cases:23.66%
controls:27.31%
cases:6.45%
controls:5.91%
cases:0.00%
controls:0.54%
—
—
—
—
—
—
cases:16.95%
controls:1.48%
22
254
71
676
6
55
87
875
0
5
93
925
—
—
—
10
8
49
534
brimonidine
S01GA07 [947915]
2.5e+00
—
—
—
—
—
—
cases:6.45%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
6
5
87
925
—
—
—
—
—
—
brimonidine
S01EA05 [21603677]
2.5e+00
—
—
—
—
—
—
cases:6.45%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
6
5
87
925
—
—
—
—
—
—
prednisolone
S03BA02 [21605202]
—
2.5e+00
—
—
—
—
—
—
—
cases:7.53%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
7
6
86
924
—
—
—
—
—
prednisolone
S01BA04 [21603621]
—
2.5e+00
—
—
—
—
—
—
—
cases:7.53%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
7
6
86
924
—
—
—
—
—
Optical coherence tomography (OCT) of ocular fundus
CK2X4 [2001301456]
—
1.1e+00
—
—
—
2.2e+00
—
—
—
cases:5.38%
controls:1.94%
—
—
—
—
—
—
cases:10.59%
controls:1.33%
—
—
—
5
18
88
912
—
—
—
9
11
76
815
—
dexamethasone; local oral
A01AC02 [21600035]
—
2.1e+00
—
—
1.0e+50
—
—
—
—
cases:8.60%
controls:1.18%
—
—
—
—
cases:12.90%
controls:0.00%
—
—
—
—
—
8
11
85
919
—
—
12
0
81
924
—
—
dexamethasone
D10AA03 [21602286]
—
2.1e+00
—
—
1.0e+50
—
—
—
—
cases:8.60%
controls:1.18%
—
—
—
—
cases:12.90%
controls:0.00%
—
—
—
—
—
8
11
85
919
—
—
12
0
81
924
—
—
dexamethasone
C05AA09 [21601613]
—
2.1e+00
—
—
1.0e+50
—
—
—
—
cases:8.60%
controls:1.18%
—
—
—
—
cases:12.90%
controls:0.00%
—
—
—
—
—
8
11
85
919
—
—
12
0
81
924
—
—
dexamethasone
S02BA06 [21605168]
—
2.1e+00
—
—
1.0e+50
—
—
—
—
cases:8.60%
controls:1.18%
—
—
—
—
cases:12.90%
controls:0.00%
—
—
—
—
—
8
11
85
919
—
—
12
0
81
924
—
—
dexamethasone
D07AB19 [21602116]
—
2.1e+00
—
—
1.0e+50
—
—
—
—
cases:8.60%
controls:1.18%
—
—
—
—
cases:12.90%
controls:0.00%
—
—
—
—
—
8
11
85
919
—
—
12
0
81
924
—
—
Puncture of vitreous body with injection of medication
CKD05 [2001301407]
1.2e+00
2.1e+00
—
—
—
1.9e+00
—
cases:5.38%
controls:1.61%
cases:8.60%
controls:1.18%
—
—
—
—
—
—
cases:7.06%
controls:1.09%
—
—
5
15
88
915
8
11
85
919
—
—
—
6
9
79
817
—
dexamethasone and antiinfectives
S01CA01 [21603652]
—
2.0e+00
—
—
1.0e+50
—
—
—
—
cases:8.60%
controls:1.29%
—
—
—
—
cases:12.90%
controls:0.00%
—
—
—
—
—
8
12
85
918
—
—
12
0
81
924
—
—
pregabalin; oral
N02BF02 [955152]
—
—
—
—
-1.0e+50
—
2.0e+00
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
cases:18.64%
controls:3.14%
—
—
—
—
0
7
93
917
—
11
17
48
525
dexamethasone and antiinfectives
S03CA01 [21605206]
—
1.9e+00
—
—
1.0e+50
—
—
—
—
cases:8.60%
controls:1.40%
—
—
—
—
cases:12.90%
controls:0.00%
—
—
—
—
—
8
13
85
917
—
—
12
0
81
924
—
—
dexamethasone; oral, parenteral
H02AB02 [21602730]
3.4e-01
1.9e+00
—
—
—
—
—
cases:5.38%
controls:3.87%
cases:9.68%
controls:1.61%
—
—
—
—
—
—
—
—
—
—
5
36
88
894
9
15
84
915
—
—
—
—
—
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 [2001310246]
1.7e+00
—
—
—
—
-1.0e+50
—
cases:11.83%
controls:2.37%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.33%
—
—
11
22
82
908
—
—
—
—
0
11
85
815
—
Bicarbonate [Moles/volume] standard in Capillary blood
19231-0 [3004490]
1.5e+00
—
—
—
—
—
-1.0e+50
cases:9.68%
controls:2.26%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.11%
9
21
84
909
—
—
—
—
—
0
6
59
536
chloramphenicol
S01AA01 [21603554]
8.2e-01
1.5e+00
—
—
—
8.7e-01
7.3e-01
cases:19.35%
controls:9.57%
cases:13.98%
controls:3.55%
—
—
—
—
—
—
cases:8.24%
controls:3.63%
cases:18.64%
controls:9.96%
18
89
75
841
13
33
80
897
—
—
—
7
30
78
796
11
54
48
488
chloramphenicol
S03AA08 [21605197]
8.2e-01
1.5e+00
—
—
—
8.7e-01
7.3e-01
cases:19.35%
controls:9.57%
cases:13.98%
controls:3.55%
—
—
—
—
—
—
cases:8.24%
controls:3.63%
cases:18.64%
controls:9.96%
18
89
75
841
13
33
80
897
—
—
—
7
30
78
796
11
54
48
488
Supine thorax X-ray examination
GD1QA [2001303648]
1.4e+00
—
—
—
—
—
—
cases:11.83%
controls:3.23%
—
—
—
—
—
—
—
—
—
—
—
—
11
30
82
900
—
—
—
—
—
—
latanoprost
S01EE01 [21603710]
1.4e+00
8.2e-01
—
—
1.6e+00
1.2e+00
1.0e+00
cases:11.83%
controls:3.33%
cases:7.53%
controls:3.44%
—
—
—
—
cases:7.53%
controls:1.62%
cases:10.59%
controls:3.51%
cases:10.17%
controls:3.87%
11
31
82
899
7
32
86
898
—
—
7
15
86
909
9
29
76
797
6
21
53
521
lercanidipine; oral
C08CA13 [21601759]
1.0e+00
1.3e+00
—
—
—
1.2e+00
4.2e-01
cases:11.83%
controls:4.62%
cases:12.90%
controls:3.76%
—
—
—
—
—
—
cases:11.76%
controls:4.00%
cases:8.47%
controls:5.72%
11
43
82
887
12
35
81
895
—
—
—
10
33
75
793
5
31
54
511
pH of Specimen
17433-4 [3019225]
1.2e+00
—
—
—
-1.0e+50
1.2e+00
1.4e+00
cases:16.13%
controls:5.27%
—
—
—
—
—
—
cases:0.00%
controls:0.54%
cases:7.06%
controls:2.30%
cases:13.56%
controls:3.69%
15
49
78
881
—
—
—
0
5
93
919
6
19
79
807
8
20
51
522
Cholesterol in HDL/Cholesterol.total [Molar ratio] in Serum or Plasma
70200-1 [42868674]
1.2e+00
6.9e-01
—
—
—
8.1e-01
1.3e+00
cases:23.66%
controls:8.49%
cases:8.60%
controls:4.52%
—
—
—
—
—
—
cases:7.06%
controls:3.27%
cases:15.25%
controls:4.80%
22
79
71
851
8
42
85
888
—
—
—
6
27
79
799
9
26
50
516
One-surface restoration
SFA10 [2001310358]
-7.5e-03
1.1e+00
—
—
—
—
2.9e-01
cases:17.20%
controls:17.31%
cases:16.13%
controls:5.81%
—
—
—
—
—
—
—
—
cases:20.34%
controls:16.05%
16
161
77
769
15
54
78
876
—
—
—
—
12
87
47
455
EKG study
11524-6 [3013512]
1.1e+00
7.4e-01
—
—
-1.0e+50
4.0e-01
5.4e-01
cases:34.41%
controls:14.62%
cases:16.13%
controls:8.39%
—
—
—
—
cases:0.00%
controls:1.52%
cases:11.76%
controls:8.23%
cases:23.73%
controls:15.31%
32
136
61
794
15
78
78
852
—
—
0
14
93
910
10
68
75
758
14
83
45
459
prednisolone; oral, parenteral
H02AB06 [21602734]
5.2e-01
9.4e-01
—
—
—
1.1e+00
8.5e-01
cases:21.51%
controls:13.98%
cases:15.05%
controls:6.45%
—
—
—
—
—
—
cases:16.47%
controls:6.05%
cases:25.42%
controls:12.73%
20
130
73
800
14
60
79
870
—
—
—
14
50
71
776
15
69
44
473
Intramuscular and subcutaneous injection
SPAT1256 [2001700357]
7.7e-01
1.0e+00
—
—
—
8.9e-01
5.1e-01
cases:26.88%
controls:14.52%
cases:17.20%
controls:6.88%
—
—
—
—
—
—
cases:11.76%
controls:5.21%
cases:16.95%
controls:10.89%
25
135
68
795
16
64
77
866
—
—
—
10
43
75
783
10
59
49
483
cetirizine; oral
R06AE07 [21603497]
-1.0e-01
—
-1.0e+50
—
—
4.1e-01
3.8e-01
cases:7.53%
controls:8.28%
—
—
cases:0.00%
controls:0.86%
—
—
—
—
cases:5.88%
controls:4.00%
cases:10.17%
controls:7.20%
7
77
86
853
—
0
8
93
922
—
—
5
33
80
793
6
39
53
503
Hysteroscopy
ULC02 [2001306644]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
93
923
—
—
—
—
—
—
tizanidine; oral
M03BX02 [21604116]
1.1e-01
8.1e-01
—
—
—
1.0e+00
7.6e-01
cases:12.90%
controls:11.72%
cases:5.38%
controls:2.47%
—
—
—
—
—
—
cases:7.06%
controls:2.66%
cases:11.86%
controls:5.90%
12
109
81
821
5
23
88
907
—
—
—
6
22
79
804
7
32
52
510
Pain in joint
M25.5 [45586941]
3.7e-01
—
—
—
—
—
3.2e-01
cases:8.60%
controls:6.13%
—
—
—
—
—
—
—
—
—
—
cases:10.17%
controls:7.56%
8
57
85
873
—
—
—
—
—
6
41
53
501
Noninfective gastroenteritis and colitis, unspecified
K52.9 [45572215]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
93
924
—
—
—
—
—
—
Unspecified dementia
F03 [45566772]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
0
8
93
922
—
—
—
—
0
5
85
821
—
Therapeutic discussion
SPAT1240 [2001700341]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
cases:0.00%
controls:1.66%
—
—
—
—
—
0
8
85
818
0
9
59
533
risedronic acid; oral
M05BA07 [21604155]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
—
Urine culture
117010004 [4024509]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
0
5
93
925
—
—
—
0
5
85
821
—
Irritable bowel syndrome with diarrhoea
K58.0 [45596336]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
93
923
—
—
—
—
—
—
indometacin; oral, parenteral, rectal
M01AB01 [21603941]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
93
924
—
—
—
—
—
—
Anesthesiology Critical Care Medicine
OMOP4821991 [45756751]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
Other specified medical care
Z51.88 [2000503765]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
Human bocavirus DNA [Presence] in Specimen by NAA with probe detection
62424-7 [40765161]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
93
921
—
—
—
—
—
—
hydrocortisone
S01CB03 [21603666]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
93
924
—
—
—
—
—
—
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
—
—
—
—
—
0
8
93
922
—
—
—
—
—
Postmenopausal bleeding
N95.0 [45567872]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
93
919
—
—
—
—
—
—
Emergency Room and Inpatient Visit
ERIP [262]
-2.7e-01
-3.5e-02
—
—
—
4.8e-01
2.2e-01
cases:10.75%
controls:13.66%
cases:6.45%
controls:6.67%
—
—
—
—
—
—
cases:11.76%
controls:7.63%
cases:18.64%
controls:15.50%
10
127
83
803
6
62
87
868
—
—
—
10
63
75
763
11
84
48
458
Vertigo/dizziness
N17 [2002000728]
—
—
—
—
—
—
8.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.47%
controls:3.87%
—
—
—
—
—
—
5
21
54
521
Striking against or struck by other object(s)
W22 [45756260]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.86%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
0
8
93
922
—
—
—
—
—
0
5
59
537
Norovirus RNA [Presence] in Stool by NAA with probe detection
7974-9 [3008909]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.40%
cases:0.00%
controls:0.75%
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
0
13
93
917
0
7
93
923
—
—
—
0
5
85
821
—
Elevated blood glucose level
R73 [45553744]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
0
5
59
537
Dental X-ray, bite-wing X-ray on one side of the mouth
EB1SA [2001301918]
-6.6e-02
6.9e-01
—
—
—
—
5.4e-03
cases:10.75%
controls:11.40%
cases:6.45%
controls:3.33%
—
—
—
—
—
—
—
—
cases:11.86%
controls:11.81%
10
106
83
824
6
31
87
899
—
—
—
—
7
64
52
478
Preretinal fibrosis of the macula
H35.38 [2000502318]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.08%
—
—
—
—
—
—
—
—
—
—
—
0
10
93
920
—
—
—
—
—
Malignant neoplasm: Bladder, unspecified
C67.9 [45571528]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
93
924
—
—
—
—
—
—
Periodontitis NOS
K05.32 [2000502730]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
—
Acute apical periodontitis of pulpal origin
K04.4 [45567286]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.40%
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
0
13
93
917
0
6
93
924
—
—
—
—
0
5
59
537
Chlamydophila pneumoniae DNA [Presence] in Specimen by NAA with probe detection
34645-2 [3031478]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
—
Chest pain, unspecified
R07.4 [45558450]
3.1e-02
—
—
—
—
—
5.6e-01
cases:7.53%
controls:7.31%
—
—
—
—
—
—
—
—
—
—
cases:10.17%
controls:6.09%
7
68
86
862
—
—
—
—
—
6
33
53
509
Hyperlipidaemia, unspecified
E78.5 [45537986]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:2.26%
cases:0.00%
controls:1.08%
—
—
—
—
—
—
—
—
—
—
0
21
93
909
0
10
93
920
—
—
—
—
—
insulin aspart; parenteral
A10AD05 [21600733]
8.5e-01
9.5e-01
—
—
—
—
—
cases:5.38%
controls:2.37%
cases:5.38%
controls:2.15%
—
—
—
—
—
—
—
—
—
—
5
22
88
908
5
20
88
910
—
—
—
—
—
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
C50.41 [2000501002]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.21%
—
—
—
—
—
—
0
12
59
530
fluocortolone
C05AA08 [21601612]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
93
922
—
—
—
—
—
—
CPAP therapy
WX723 [2001310826]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.86%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
0
8
93
922
—
—
—
—
—
0
5
59
537
budesonide; oral, sublingual
A07EA06 [21600658]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
diltiazem; oral
C08DB01 [21601771]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.29%
—
—
—
—
—
—
0
7
59
535
Calprotectin [Mass/mass] in Stool
38445-3 [3048689]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.94%
cases:0.00%
controls:3.51%
—
—
—
—
—
0
16
85
810
0
19
59
523
Obesity due to excess calories
E66.01 [2000501501]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.75%
cases:0.00%
controls:0.65%
—
—
—
—
—
—
cases:0.00%
controls:0.61%
cases:0.00%
controls:0.92%
0
7
93
923
0
6
93
924
—
—
—
0
5
85
821
0
5
59
537
Lymphocyte T-cell and B-cell and Natural killer subsets panel - Blood
80721-4 [21493690]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
—
Ulcer of lower limb, not elsewhere classified
L97 [45591659]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
0
6
93
924
—
—
—
—
—
0
5
59
537
Seborrhoeic dermatitis
L21 [45596367]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
93
924
—
—
—
—
—
—
trimethoprim; oral, parenteral
J01EA01 [21602931]
-1.9e-01
—
—
—
—
—
2.3e-02
cases:7.53%
controls:8.92%
—
—
—
—
—
—
—
—
—
—
cases:10.17%
controls:9.96%
7
83
86
847
—
—
—
—
—
6
54
53
488
Mitral (valve) insufficiency
I34.09 [2000502484]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.51%
cases:0.00%
controls:0.54%
—
—
—
—
—
—
cases:0.00%
controls:0.85%
cases:0.00%
controls:1.66%
0
14
93
916
0
5
93
925
—
—
—
0
7
85
819
0
9
59
533
Neoplasm of uncertain or unknown behaviour: Skin
D48.5 [45586113]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.51%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
0
14
93
916
—
—
—
—
—
0
5
59
537
Skin infection other
S76 [2002001040]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.08%
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
0
10
93
920
0
5
93
925
—
—
—
—
—
Diabetes, insulin-treated
103 [2001600103]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
Sensorineural hearing loss, bilateral
H90.3 [45576850]
1.3e-01
—
—
—
-1.0e+50
—
6.7e-01
cases:7.53%
controls:6.67%
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
cases:11.86%
controls:6.46%
7
62
86
868
—
—
—
0
5
93
919
—
7
35
52
507
rivastigmine; oral, transdermal
N06DA03 [21604796]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
cases:0.00%
controls:2.03%
—
—
—
—
—
0
5
85
821
0
11
59
531
Parathyrin.intact [Moles/volume] in Serum or Plasma
14866-8 [3010566]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
other preparations, combinations; ointment
C05AX03 [21601631]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.37%
cases:0.00%
controls:1.18%
—
—
—
—
—
—
cases:0.00%
controls:1.94%
—
—
0
22
93
908
0
11
93
919
—
—
—
0
16
85
810
—
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]
-3.0e-02
-1.0e+50
—
—
—
—
—
cases:7.53%
controls:7.74%
cases:0.00%
controls:2.47%
—
—
—
—
—
—
—
—
—
—
7
72
86
858
0
23
93
907
—
—
—
—
—
Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma
14685-2 [3009035]
4.6e-01
—
—
—
—
—
-4.8e-02
cases:10.75%
controls:7.10%
—
—
—
—
—
—
—
—
—
—
cases:8.47%
controls:8.86%
10
66
83
864
—
—
—
—
—
5
48
54
494
Specialised imaging for glaucoma
CS5Z4 [2001301479]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
93
923
—
—
—
—
—
—
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
2.2e-01
2.3e-01
5.5e-02
—
-1.1e-01
2.1e-01
3.8e-01
cases:52.69%
controls:47.31%
cases:33.33%
controls:28.49%
cases:6.45%
controls:6.13%
—
—
cases:5.38%
controls:5.95%
cases:31.76%
controls:27.36%
cases:61.02%
controls:51.66%
49
440
44
490
31
265
62
665
6
57
87
873
—
5
55
88
869
27
226
58
600
36
280
23
262
Special examination, unspecified
Z01.9 [45576123]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
cases:0.00%
controls:0.92%
—
—
—
—
—
0
6
85
820
0
5
59
537
Heart failure
I50 [45581779]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.18%
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.03%
0
11
93
919
0
5
93
925
—
—
—
—
0
11
59
531
Immunoglobulin light chains.free panel - Serum
57778-3 [40760888]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
0
8
93
922
—
—
—
0
6
85
820
—
Human epididymis protein 4 [Moles/volume] in Serum or Plasma
55180-4 [40758310]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
93
924
—
—
—
—
—
—
Benign lipomatous neoplasm of skin and subcutaneous tissue of trunk
D17.1 [45566667]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
93
924
—
—
—
—
—
—
Chronic kidney disease, unspecified
N18.9 [45553438]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.51%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
0
14
93
916
—
—
—
—
0
10
85
816
—
Disorientation, unspecified
R41.0 [45558469]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.54%
cases:0.00%
controls:0.54%
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
0
5
93
925
0
5
93
925
—
—
—
0
5
85
821
—
Reticulocytes [#/volume] in Blood
14196-0 [3023520]
5.9e-01
—
—
—
—
—
—
cases:7.53%
controls:4.30%
—
—
—
—
—
—
—
—
—
—
—
—
7
40
86
890
—
—
—
—
—
—
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
2.4e-01
2.4e-01
4.8e-01
—
5.6e-02
4.3e-01
2.7e-01
cases:51.61%
controls:45.59%
cases:43.01%
controls:37.20%
cases:11.83%
controls:7.63%
—
—
cases:7.53%
controls:7.14%
cases:47.06%
controls:36.56%
cases:54.24%
controls:47.42%
48
424
45
506
40
346
53
584
11
71
82
859
—
7
66
86
858
40
302
45
524
32
257
27
285
Spinalanesthesia
WX320 [2001310799]
-2.1e-02
—
—
—
—
—
8.8e-01
cases:5.38%
controls:5.48%
—
—
—
—
—
—
—
—
—
—
cases:8.47%
controls:3.69%
5
51
88
879
—
—
—
—
—
5
20
54
522
nimesulide; oral
M01AX17 [21604007]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.08%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.85%
0
10
93
920
—
—
—
—
—
0
10
59
532
Wrist symptom/complaint
L11 [2002000635]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.48%
—
—
—
—
—
—
0
8
59
534
alfuzosin; oral
G04CA01 [21602668]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.08%
—
—
—
—
—
—
—
—
0
10
93
914
—
—
Triglyceride [Moles/volume] in Serum or Plasma
14927-8 [3025839]
—
-1.2e-01
—
—
—
1.5e-01
—
—
—
cases:5.38%
controls:6.02%
—
—
—
—
—
—
cases:8.24%
controls:7.14%
—
—
—
5
56
88
874
—
—
—
7
59
78
767
—
omeprazole; oral, parenteral
A02BC01 [21600096]
—
—
—
—
—
—
7.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.47%
controls:4.06%
—
—
—
—
—
—
5
22
54
520
Albumin [Mass/time] in Urine collected for unspecified duration
49002-9 [3050449]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.66%
—
0
5
93
925
—
—
—
—
0
9
59
533
Seropositive rheumatoid arthritis, unspecified
M05.9 [45553050]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
—
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
3.9e-01
-1.1e-01
—
—
—
3.4e-01
6.4e-01
cases:29.03%
controls:21.61%
cases:9.68%
controls:10.65%
—
—
—
—
—
—
cases:15.29%
controls:11.38%
cases:35.59%
controls:22.51%
27
201
66
729
9
99
84
831
—
—
—
13
94
72
732
21
122
38
420
Medical Oncology
90 [38004507]
3.6e-01
—
—
—
—
—
—
cases:7.53%
controls:5.38%
—
—
—
—
—
—
—
—
—
—
—
—
7
50
86
880
—
—
—
—
—
—
Diabetes, non-insulin-treated
215 [2001600211]
-1.0e-01
-1.0e+50
—
—
—
-1.0e+50
7.3e-01
cases:5.38%
controls:5.91%
cases:0.00%
controls:0.75%
—
—
—
—
—
—
cases:0.00%
controls:0.85%
cases:10.17%
controls:5.17%
5
55
88
875
0
7
93
923
—
—
—
0
7
85
819
6
28
53
514
Disease/condition unspecnature/site
A99 [2002000232]
1.2e+00
—
—
—
—
—
1.6e+00
cases:6.45%
controls:2.04%
—
—
—
—
—
—
—
—
—
—
cases:8.47%
controls:1.85%
6
19
87
911
—
—
—
—
—
5
10
54
532
Opening and preparing the root canals, complicated
SGA03 [2001310381]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
93
915
—
—
—
—
—
—
Cystoscopy
UKC02 [2001306005]
3.4e-01
—
—
—
—
—
—
cases:5.38%
controls:3.87%
—
—
—
—
—
—
—
—
—
—
—
—
5
36
88
894
—
—
—
—
—
—
Fracture of metatarsal bone
S92.3 [45574912]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
0
5
59
537
Lactate [Moles/volume] in Arterial blood
2518-9 [3018405]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.08%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.21%
0
10
93
920
—
—
—
—
—
0
12
59
530
ambroxol; oral
R05CB06 [21603385]
9.6e-01
—
—
—
—
—
—
cases:6.45%
controls:2.58%
—
—
—
—
—
—
—
—
—
—
—
—
6
24
87
906
—
—
—
—
—
—
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
-3.5e-02
—
—
—
-1.0e+50
—
4.7e-02
cases:6.45%
controls:6.67%
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
cases:8.47%
controls:8.12%
6
62
87
868
—
—
—
0
6
93
918
—
5
44
54
498
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
2.6e-01
—
—
—
—
—
—
cases:7.53%
controls:5.91%
—
—
—
—
—
—
—
—
—
—
—
—
7
55
86
875
—
—
—
—
—
—
Difficulties in perfomrming procedure
ZXD30 [2001311389]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
—
Protein.monoclonal band 3 [Mass/volume] in Serum or Plasma by Electrophoresis
50796-2 [3029338]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.51%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
0
14
93
916
—
—
—
—
0
5
85
821
—
Glucose [Moles/volume] in Capillary blood
51596-5 [3040151]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
0
5
59
537
Smith extractable nuclear Ab [Units/volume] in Serum
11090-8 [3016921]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
0
5
85
821
—
Type 2 diabetes mellitus
E11 [45571656]
-2.5e-01
—
—
—
—
—
4.3e-01
cases:6.45%
controls:8.17%
—
—
—
—
—
—
—
—
—
—
cases:10.17%
controls:6.83%
6
76
87
854
—
—
—
—
—
6
37
53
505
Methemoglobin/Hemoglobin.total in Arterial blood
2615-3 [3006217]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.83%
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
0
17
93
913
0
5
93
925
—
—
—
—
—
Excision of other lesion extending through all layers of skin in head or neck
QAE10 [2001309784]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
—
0
8
85
818
—
General Surgery
2 [38004447]
4.2e-01
6.3e-01
-1.0e+50
—
-1.0e+50
—
-3.9e-02
cases:19.35%
controls:13.66%
cases:6.45%
controls:3.55%
cases:0.00%
controls:0.65%
—
—
cases:0.00%
controls:0.87%
—
—
cases:13.56%
controls:14.02%
18
127
75
803
6
33
87
897
0
6
93
924
—
0
8
93
916
—
8
76
51
466
metformin and sitagliptin
A10BD07 [21600772]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
cases:0.00%
controls:0.61%
cases:0.00%
controls:0.92%
—
0
6
93
924
—
—
—
0
5
85
821
0
5
59
537
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
1.5e-01
—
—
—
—
8.5e-01
—
cases:8.60%
controls:7.53%
—
—
—
—
—
—
—
—
cases:7.06%
controls:3.15%
—
—
8
70
85
860
—
—
—
—
6
26
79
800
—
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
6.6e-01
-1.0e+50
—
—
—
-1.0e+50
—
cases:6.45%
controls:3.44%
cases:0.00%
controls:1.72%
—
—
—
—
—
—
cases:0.00%
controls:1.94%
—
—
6
32
87
898
0
16
93
914
—
—
—
0
16
85
810
—
Laboratory Visit
OMOP4822461 [32036]
3.7e-02
2.3e-01
1.9e-01
1.7e+00
4.1e-01
3.7e-01
3.2e-02
cases:63.44%
controls:62.58%
cases:61.29%
controls:55.59%
cases:22.58%
controls:19.46%
cases:6.45%
controls:1.29%
cases:23.66%
controls:16.99%
cases:63.53%
controls:54.60%
cases:69.49%
controls:68.82%
59
582
34
348
57
517
36
413
21
181
72
749
6
12
87
918
22
157
71
767
54
451
31
375
41
373
18
169
Hemoglobin.gastrointestinal [Presence] in Stool
2335-8 [3016251]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:2.26%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.03%
0
21
93
909
—
—
—
—
—
0
11
59
531
folic acid; oral, parenteral
B03BB01 [21601129]
—
—
-1.0e+50
—
-1.0e+50
1.2e+00
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
cases:0.00%
controls:0.76%
cases:7.06%
controls:2.18%
—
—
—
—
0
8
93
922
—
0
7
93
917
6
18
79
808
—
Intraoral radiographic dental examination
EB1AA [2001301903]
1.9e-01
4.7e-01
—
—
—
4.0e-01
-1.2e-02
cases:20.43%
controls:17.53%
cases:7.53%
controls:4.84%
—
—
—
—
—
—
cases:7.06%
controls:4.84%
cases:11.86%
controls:11.99%
19
163
74
767
7
45
86
885
—
—
—
6
40
79
786
7
65
52
477
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
5.3e-01
—
—
—
—
—
7.9e-01
cases:13.98%
controls:8.71%
—
—
—
—
—
—
—
—
—
—
cases:13.56%
controls:6.64%
13
81
80
849
—
—
—
—
—
8
36
51
506
Short blood count panel - Blood
55429-5 [40758558]
—
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
cases:0.00%
controls:3.15%
—
—
—
—
0
9
93
921
—
—
0
26
85
800
—
Emergency Medicine
93 [38004510]
3.1e-01
6.1e-01
1.4e+00
—
—
5.1e-01
4.5e-01
cases:33.33%
controls:26.88%
cases:21.51%
controls:13.01%
cases:6.45%
controls:1.72%
—
—
—
—
cases:21.18%
controls:13.92%
cases:38.98%
controls:28.97%
31
250
62
680
20
121
73
809
6
16
87
914
—
—
18
115
67
711
23
157
36
385
Chronic gingivitis
K05.18 [2000502721]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
93
923
—
—
—
—
—
—
Carpal tunnel syndrome
G56.0 [45566891]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
Traumatic subdural haemorrhage
S06.5 [45563422]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
93
924
—
—
—
—
—
—
Respiratory symptom/complaint other
R29 [2002000898]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
93
924
—
—
—
—
—
—
Injury of muscle(s) and tendon(s) of the rotator cuff of shoulder
S46.0 [45544769]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
0
5
59
537
Cardiodefibrillation
TFP20 [2001303224]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
93
921
—
—
—
—
—
—
tamsulosin and dutasteride
G04CA52 [21602673]
—
—
-1.0e+50
—
-1.0e+50
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:0.97%
—
—
cases:0.00%
controls:0.54%
—
—
cases:0.00%
controls:2.77%
—
—
0
9
93
921
—
0
5
93
919
—
0
15
59
527
Sepsis due to other Gram-negative organisms
A41.5 [45556902]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
Internal derangement of knee, unspecified
M23.9 [45567507]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
0
5
59
537
Speech audiometry
252592009 [4091138]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.61%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
0
15
93
915
—
—
—
—
0
5
85
821
—
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease
206 [2001600204]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.29%
—
0
5
93
925
—
—
—
—
0
7
59
535
Benign neoplasm: Caecum
D12.0 [45586086]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.08%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
93
920
—
—
—
—
—
—
Preparation of an aid
R5120 [2001310247]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
93
923
—
—
—
—
—
—
Mild cognitive disorder
F06.7 [45605450]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
93
923
—
—
—
—
—
—
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.4e-01
3.1e-01
4.7e-01
—
1.2e-01
4.5e-01
-3.2e-02
cases:63.44%
controls:60.22%
cases:55.91%
controls:48.17%
cases:15.05%
controls:10.00%
—
—
cases:10.75%
controls:9.63%
cases:57.65%
controls:46.37%
cases:64.41%
controls:65.13%
59
560
34
370
52
448
41
482
14
93
79
837
—
10
89
83
835
49
383
36
443
38
353
21
189
Standard cardiac ultrasound examination
FM1AE [2001303278]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
—
0
10
85
816
—
calcium carbonate
A02AC01 [21600065]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
cases:0.00%
controls:0.92%
—
—
—
—
—
0
5
85
821
0
5
59
537
Extraction of tooth
EBA00 [2001301923]
4.0e-01
—
—
—
—
1.1e+00
3.2e-01
cases:8.60%
controls:5.91%
—
—
—
—
—
—
—
—
cases:5.88%
controls:1.94%
cases:8.47%
controls:6.27%
8
55
85
875
—
—
—
—
5
16
80
810
5
34
54
508
Bicarbonate [Moles/volume] in Capillary blood
1961-2 [3015235]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
0
7
93
923
—
—
—
—
—
Asthma, unspecified
J45.9 [45562456]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
0
8
93
922
—
0
5
93
919
—
—
Sicca syndrome [Sjögren]
M35.0 [45562711]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
0
5
85
821
—
pneumococcus, purified polysaccharides antigen conjugated
J07AL02 [21601313]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
Ear pain/earache
H01 [2002000475]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:2.15%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.77%
0
20
93
910
—
—
—
—
—
0
15
59
527
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
3.5e-01
6.5e-01
—
—
—
2.0e-01
4.4e-01
cases:25.81%
controls:19.68%
cases:16.13%
controls:9.14%
—
—
—
—
—
—
cases:10.59%
controls:8.84%
cases:27.12%
controls:19.37%
24
183
69
747
15
85
78
845
—
—
—
9
73
76
753
16
105
43
437
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
6.2e-01
—
—
—
—
—
—
cases:7.53%
controls:4.19%
—
—
—
—
—
—
—
—
—
—
—
—
7
39
86
891
—
—
—
—
—
—
Fracture of neck of femur
S72.0 [45593656]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.48%
—
—
—
—
—
—
0
8
59
534
fluticasone; nasal
R01AD08 [21605050]
3.0e-01
—
—
—
-1.0e+50
—
1.8e-01
cases:11.83%
controls:9.03%
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
cases:8.47%
controls:7.20%
11
84
82
846
—
—
—
0
5
93
919
—
5
39
54
503
CD3-CD16+CD56+ (Natural killer) cells/cells in Blood
8112-5 [3027831]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
—
Outpatient Hospital
22 [8756]
6.4e-01
6.1e-01
—
1.0e+50
—
9.1e-01
4.9e-01
cases:34.41%
controls:21.72%
cases:10.75%
controls:6.13%
—
—
cases:11.83%
controls:0.00%
—
—
cases:11.76%
controls:5.08%
cases:28.81%
controls:19.93%
32
202
61
728
10
57
83
873
—
11
0
82
930
—
10
42
75
784
17
108
42
434
losartan; oral
C09CA01 [21601824]
0.0e+00
-3.0e-01
-1.0e+50
—
—
-6.2e-01
—
cases:10.75%
controls:10.75%
cases:7.53%
controls:9.89%
cases:0.00%
controls:2.26%
—
—
—
—
cases:5.88%
controls:10.41%
—
—
10
100
83
830
7
92
86
838
0
21
93
909
—
—
5
86
80
740
—
sertraline; oral
N06AB06 [21604714]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.08%
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
0
10
93
920
—
—
—
0
8
85
818
—
Cervicobrachial syndrome
M53.1 [45567577]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.86%
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
0
8
93
922
0
6
93
924
—
—
—
—
—
Anaemia vit B12/folate deficiency
B81 [2002000292]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
cases:0.00%
controls:0.92%
—
—
—
—
—
0
8
85
818
0
5
59
537
Cholesterol in LDL [Moles/volume] in Serum or Plasma
22748-8 [3001308]
3.5e-01
5.0e-03
8.0e-01
—
-1.0e+50
2.3e-02
-5.1e-01
cases:60.22%
controls:51.51%
cases:31.18%
controls:31.08%
cases:6.45%
controls:3.01%
—
—
cases:0.00%
controls:2.38%
cases:32.94%
controls:32.45%
cases:42.37%
controls:55.17%
56
479
37
451
29
289
64
641
6
28
87
902
—
0
22
93
902
28
268
57
558
25
299
34
243
Unspecified kidney failure
N19 [45601718]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
93
924
—
—
—
—
—
—
chlorhexidine
S02AA09 [21605155]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
cases:0.00%
controls:1.33%
—
—
—
0
7
93
923
—
—
—
0
11
85
815
—
Urinary symptom/complaint other
U29 [2002001149]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.54%
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
0
5
93
925
0
5
93
925
—
—
—
—
—
Volume of Urine
28009-9 [3036603]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
93
924
—
—
—
—
—
—
Pleural plaque with presence of asbestos
J92.0 [45567277]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
—
Malignant neoplasm of breast
C50 [45571518]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.29%
—
—
—
—
—
—
0
7
59
535
naproxcinod
M01AE18 [40254094]
—
—
—
—
—
—
8.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.86%
controls:5.72%
—
—
—
—
—
—
7
31
52
511
Dental examination
Z01.2 [45581002]
5.3e-01
4.2e-01
—
—
—
2.3e-01
3.0e-01
cases:18.28%
controls:11.61%
cases:7.53%
controls:5.05%
—
—
—
—
—
—
cases:5.88%
controls:4.72%
cases:16.95%
controls:13.10%
17
108
76
822
7
47
86
883
—
—
—
5
39
80
787
10
71
49
471
Cardiovascular sympt/complt other
K29 [2002000556]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.48%
0
5
93
925
—
—
—
—
—
0
8
59
534
Other hammer toe(s) (acquired)
M20.4 [45562664]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.97%
cases:0.00%
controls:0.54%
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
0
9
93
921
0
5
93
925
—
—
—
0
7
85
819
—
Puncture of maxillary antrum
TDM10 [2001301819]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
93
924
—
—
—
—
—
—
diclofenac; ointment
M02AA15 [21604051]
1.0e+00
—
—
—
—
-1.0e+50
—
cases:8.60%
controls:3.23%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.42%
—
—
8
30
85
900
—
—
—
—
0
20
85
806
—
Vision screening
408760009 [4237318]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.65%
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
0
6
93
924
0
5
93
925
—
—
—
—
—
Eyelid symptom/complaint
F16 [2002000407]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
93
924
—
—
—
—
—
—
Internal Medicine
11 [38004456]
2.3e-01
5.0e-02
—
—
—
1.5e-01
5.9e-01
cases:30.11%
controls:25.59%
cases:9.68%
controls:9.25%
—
—
—
—
—
—
cases:11.76%
controls:10.29%
cases:32.20%
controls:20.85%
28
238
65
692
9
86
84
844
—
—
—
10
85
75
741
19
113
40
429
Acute vaginitis
N76.0 [45543891]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.65%
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
0
6
93
924
0
5
93
925
—
—
—
—
—
dextromethorphan; oral
R05DA09 [21603404]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
0
6
93
924
—
—
—
—
—
Pulmonary Disease
29 [38004472]
-2.6e-01
1.5e-01
-1.0e+50
—
-1.0e+50
5.5e-01
—
cases:10.75%
controls:13.55%
cases:6.45%
controls:5.59%
cases:0.00%
controls:1.51%
—
—
cases:0.00%
controls:1.62%
cases:10.59%
controls:6.42%
—
—
10
126
83
804
6
52
87
878
0
14
93
916
—
0
15
93
909
9
53
76
773
—
Destruction of lesion of head or neck
QAA25 [2001309763]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
0
5
59
537
Parainfluenza type 4 nucleic acid detection
810871000000102 [44806118]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
—
Boil/carbuncle
S10 [2002000975]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.85%
—
—
—
—
—
—
0
10
59
532
Other extracapsular cataract operation using phakoemulsification technique
CJE99 [2001301346]
—
—
1.0e+50
1.0e+50
—
—
—
—
—
—
—
cases:6.45%
controls:0.00%
cases:9.68%
controls:0.00%
—
—
—
—
—
—
—
—
6
0
87
930
9
0
84
930
—
—
—
triamcinolone and antiseptics
D07BB03 [21602150]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
cases:0.00%
controls:1.33%
—
—
—
0
8
93
922
—
—
—
0
11
85
815
—
Cryotherapy
ZXC50 [2001311370]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.97%
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
0
9
93
921
0
5
93
925
—
—
—
—
—
Nail symptom/complaint
S22 [2002000987]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
0
5
85
821
—
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
-6.6e-02
-1.0e+50
—
—
—
—
2.6e-01
cases:8.60%
controls:9.14%
cases:0.00%
controls:3.55%
—
—
—
—
—
—
—
—
cases:11.86%
controls:9.41%
8
85
85
845
0
33
93
897
—
—
—
—
7
51
52
491
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
4.9e-01
9.1e-01
—
—
—
1.4e+00
1.2e+00
cases:13.98%
controls:9.03%
cases:6.45%
controls:2.69%
—
—
—
—
—
—
cases:8.24%
controls:2.18%
cases:18.64%
controls:6.27%
13
84
80
846
6
25
87
905
—
—
—
7
18
78
808
11
34
48
508
Pneumonia, unspecified
J18.9 [45601123]
—
—
—
—
—
—
4.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.17%
controls:6.64%
—
—
—
—
—
—
6
36
53
506
long-acting sulfonamides - combinations
J01ED20 [21602959]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
Transurethral resection of prostate
KED22 [2001306138]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.29%
0
7
93
923
—
—
—
—
—
0
7
59
535
Benign neoplasm: Rectum
D12.8 [45595734]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
0
7
93
923
—
—
—
—
—
0
5
59
537
Clinical photography of mouth and teeth
SBB00 [2001310298]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
93
923
—
—
—
—
—
—
triamcinolone; nasal
R01AD11 [21605052]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
—
Leukocytes [Presence] in Urine
33052-2 [3045414]
—
—
—
—
—
—
8.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.17%
controls:4.80%
—
—
—
—
—
—
6
26
53
516
Periradicular abscess with fistula to mouth
K04.62 [2000502707]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
93
924
—
—
—
—
—
—
insulin detemir; parenteral
A10AE05 [21600740]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.51%
cases:0.00%
controls:1.29%
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
0
14
93
916
0
12
93
918
—
—
—
0
10
85
816
—
Sedation and analgesia
WX002 [2001310758]
-1.9e-01
—
—
—
—
—
—
cases:5.38%
controls:6.45%
—
—
—
—
—
—
—
—
—
—
—
—
5
60
88
870
—
—
—
—
—
—
levothyroxine sodium; oral, parenteral
H03AA01 [21602754]
-2.6e-01
-1.5e-01
—
—
-1.0e+50
-1.3e-01
1.6e-01
cases:9.68%
controls:12.15%
cases:10.75%
controls:12.26%
—
—
—
—
cases:0.00%
controls:3.90%
cases:10.59%
controls:11.86%
cases:15.25%
controls:13.28%
9
113
84
817
10
114
83
816
—
—
0
36
93
888
9
98
76
728
9
72
50
470
Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection
21613-5 [3006093]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.08%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
0
10
93
920
—
—
—
—
—
0
5
59
537
mometasone
D07AC13 [21602132]
2.6e-01
—
—
—
—
—
—
cases:6.45%
controls:5.05%
—
—
—
—
—
—
—
—
—
—
—
—
6
47
87
883
—
—
—
—
—
—
CBC panel - Blood by Automated count
58410-2 [40761511]
2.8e-01
2.8e-01
4.8e-01
—
8.1e-02
2.1e-01
2.5e-01
cases:59.14%
controls:52.37%
cases:35.48%
controls:29.46%
cases:9.68%
controls:6.24%
—
—
cases:5.38%
controls:4.98%
cases:32.94%
controls:28.45%
cases:55.93%
controls:49.63%
55
487
38
443
33
274
60
656
9
58
84
872
—
5
46
88
878
28
235
57
591
33
269
26
273
Angiography of heart and/or coronary arteries
FN1AC [2001302996]
9.3e-02
-1.0e+50
—
—
—
—
-1.0e+50
cases:6.45%
controls:5.91%
cases:0.00%
controls:1.72%
—
—
—
—
—
—
—
—
cases:0.00%
controls:4.43%
6
55
87
875
0
16
93
914
—
—
—
—
0
24
59
518
Presence of prosthetic heart valve
Z95.2 [45542495]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
0
5
93
925
—
—
—
—
0
5
85
821
—
Nose bleed/epistaxis
R06 [2002000887]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
93
924
—
—
—
—
—
—
meloxicam; oral, parenteral, rectal
M01AC06 [21603965]
4.5e-01
-1.0e+50
—
—
—
—
—
cases:6.45%
controls:4.19%
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
6
39
87
891
0
6
93
924
—
—
—
—
—
Other difficulties with micturition
R39.1 [45534441]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
93
924
—
—
—
—
—
—
Basic examination of mouth
SAA02 [2001310275]
-1.8e-01
4.4e-01
—
—
—
1.4e-01
-1.0e-01
cases:19.35%
controls:22.26%
cases:11.83%
controls:7.96%
—
—
—
—
—
—
cases:8.24%
controls:7.26%
cases:23.73%
controls:25.65%
18
207
75
723
11
74
82
856
—
—
—
7
60
78
766
14
139
45
403
antibiotics in combination with corticosteroids
D01AA20 [21601918]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.18%
cases:0.00%
controls:0.54%
—
—
—
—
—
—
cases:0.00%
controls:1.21%
cases:0.00%
controls:1.85%
0
11
93
919
0
5
93
925
—
—
—
0
10
85
816
0
10
59
532
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.45%
—
—
—
—
—
—
—
0
12
85
814
—
Coloscopy
UJF32 [2001305029]
9.0e-01
—
—
—
—
—
4.9e-01
cases:11.83%
controls:5.16%
—
—
—
—
—
—
—
—
—
—
cases:8.47%
controls:5.35%
11
48
82
882
—
—
—
—
—
5
29
54
513
Epstein Barr virus Ab [Presence] in Serum
49178-7 [3048929]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
93
924
—
—
—
—
—
—
indometacin
C01EB03 [21600365]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
93
924
—
—
—
—
—
—
fluocinolone acetonide and antiinfectives
S02CA05 [21605177]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
—
—
—
—
—
0
8
93
922
—
—
—
—
—
Root filling of tooth with onetwo root canals
SGB20 [2001310389]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
93
921
—
—
—
—
—
—
Oxygen [Partial pressure] adjusted to patient's actual temperature in Venous blood
19258-3 [3004529]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:1.51%
—
—
—
—
—
—
cases:0.00%
controls:1.33%
cases:0.00%
controls:2.40%
—
0
14
93
916
—
—
—
0
11
85
815
0
13
59
529
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
-9.8e-02
2.6e-01
—
—
—
4.4e-01
4.0e-02
cases:15.05%
controls:16.34%
cases:7.53%
controls:5.91%
—
—
—
—
—
—
cases:9.41%
controls:6.30%
cases:13.56%
controls:13.10%
14
152
79
778
7
55
86
875
—
—
—
8
52
77
774
8
71
51
471
Transferrin.carbohydrate deficient.disialo/Transferrin.total in Serum or Plasma
21573-1 [3003031]
1.3e+00
—
—
—
—
-1.0e+50
-1.0e+50
cases:6.45%
controls:1.83%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
cases:0.00%
controls:2.03%
6
17
87
913
—
—
—
—
0
7
85
819
0
11
59
531
Counselling and guidance related to ageing
SPAT1304 [2001700405]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.21%
—
—
—
—
—
—
0
12
59
530
beclometasone; inhalant
R03BA01 [21603284]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.58%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.33%
—
—
0
24
93
906
—
—
—
—
0
11
85
815
—
Varicose veins of lower extremities without ulcer or inflammation
I83.9 [45552859]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.11%
0
7
93
923
—
—
—
—
—
0
6
59
536
promethazine, combinations
R06AD52 [21603489]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
Two-surface restoration
SFA20 [2001310359]
1.7e-01
4.7e-01
-1.0e+50
—
—
1.9e-01
1.7e-01
cases:22.58%
controls:19.68%
cases:10.75%
controls:6.99%
cases:0.00%
controls:0.65%
—
—
—
—
cases:8.24%
controls:6.90%
cases:23.73%
controls:20.85%
21
183
72
747
10
65
83
865
0
6
93
924
—
—
7
57
78
769
14
113
45
429
triamcinolone and antiinfectives
S02CA04 [21605176]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
—
Ear symptom/complaint other
H29 [2002000484]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.69%
—
—
—
—
—
—
0
20
59
522
Presence of orthopaedic joint implants
Z96.6 [45600385]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
0
5
59
537
Bacteria identified based on 16S rRNA gene [Identifier] in Specimen by Sequencing
66885-5 [40769539]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
0
5
85
821
—
levetiracetam; oral, parenteral
N03AX14 [21604436]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.65%
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
0
6
93
924
0
5
93
925
—
—
—
—
—
Cough
R05 [45606792]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.40%
—
—
—
—
—
—
—
—
—
—
—
0
13
93
917
—
—
—
—
—
hydrocortisone buteprate
D07AB11 [21602115]
2.5e-02
—
—
—
—
—
2.7e-01
cases:9.68%
controls:9.46%
—
—
—
—
—
—
—
—
—
—
cases:10.17%
controls:7.93%
9
88
84
842
—
—
—
—
—
6
43
53
499
Besnier prurigo
L20.0 [45562534]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
93
923
—
—
—
—
—
—
Memory disturbance
P20 [2002000816]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
0
6
93
924
—
—
—
—
Pain, unspecified
R52.9 [45544151]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.85%
—
—
—
—
—
—
0
10
59
532
Lipid disorder
T93 [2002001134]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.61%
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.21%
0
15
93
915
0
6
93
924
—
—
—
—
0
12
59
530
betaxolol; oral
C07AB05 [21601687]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
cases:0.00%
controls:0.92%
0
11
93
919
—
—
—
—
0
5
85
821
0
5
59
537
Carcinoma in situ: Skin of scalp and neck
D04.4 [45581275]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
—
Puncture of anterior chamber of eye with irrigation
CHB10 [2001301241]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:12.90%
controls:0.00%
—
—
—
—
—
—
—
—
—
12
0
81
930
—
—
—
Otitis externa
H70 [2002000525]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
—
sitagliptin; oral
A10BH01 [21600784]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:2.04%
cases:0.00%
controls:0.97%
—
—
cases:0.00%
controls:0.87%
cases:0.00%
controls:2.18%
cases:0.00%
controls:2.77%
—
0
19
93
911
0
9
93
921
—
0
8
93
916
0
18
85
808
0
15
59
527
oxcarbazepine; oral
N03AF02 [21604418]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
cases:0.00%
controls:1.11%
0
7
93
923
—
—
—
—
0
6
85
820
0
6
59
536
Epstein Barr virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
43730-1 [3043849]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
93
924
—
—
—
—
—
—
Spermatocele
N43.4 [45558155]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
93
924
—
—
—
—
—
—
racecadotril
A07XA04 [21600677]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
—
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.4e-01
3.1e-01
4.7e-01
—
1.2e-01
4.4e-01
-4.0e-02
cases:63.44%
controls:60.22%
cases:55.91%
controls:48.17%
cases:15.05%
controls:10.00%
—
—
cases:10.75%
controls:9.63%
cases:57.65%
controls:46.61%
cases:64.41%
controls:65.31%
59
560
34
370
52
448
41
482
14
93
79
837
—
10
89
83
835
49
385
36
441
38
354
21
188
Hemoglobin [Entitic mass] in Reticulocytes
42810-2 [3029080]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
0
5
93
925
—
—
—
—
—
0
5
59
537
Platelets [#/volume] in Blood
26515-7 [3007461]
1.4e-01
3.1e-01
4.8e-01
—
1.2e-01
4.5e-01
-3.2e-02
cases:63.44%
controls:60.11%
cases:55.91%
controls:48.28%
cases:15.05%
controls:9.89%
—
—
cases:10.75%
controls:9.63%
cases:57.65%
controls:46.37%
cases:64.41%
controls:65.13%
59
559
34
371
52
449
41
481
14
92
79
838
—
10
89
83
835
49
383
36
443
38
353
21
189
nilvadipine; oral
C08CA10 [21601756]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
—
Dental calculus supragingival
K03.64 [2000502689]
5.7e-01
—
—
—
—
—
3.6e-01
cases:9.68%
controls:5.70%
—
—
—
—
—
—
—
—
—
—
cases:8.47%
controls:6.09%
9
53
84
877
—
—
—
—
—
5
33
54
509
Bicarbonate [Moles/volume] in Venous blood
14627-4 [3027273]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.40%
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
0
13
93
917
—
—
—
0
8
85
818
—
amitriptyline; oral, parenteral
N06AA09 [21604696]
7.8e-01
1.0e+00
—
—
—
7.4e-01
7.8e-01
cases:11.83%
controls:5.81%
cases:7.53%
controls:2.80%
—
—
—
—
—
—
cases:5.88%
controls:2.91%
cases:8.47%
controls:4.06%
11
54
82
876
7
26
86
904
—
—
—
5
24
80
802
5
22
54
520
Prostate specific Ag [Mass/volume] in Serum or Plasma
2857-1 [3013603]
-9.8e-02
-5.3e-01
—
—
-1.0e+50
5.0e-02
3.8e-02
cases:18.28%
controls:19.78%
cases:7.53%
controls:12.15%
—
—
—
—
cases:0.00%
controls:1.08%
cases:11.76%
controls:11.26%
cases:18.64%
controls:18.08%
17
184
76
746
7
113
86
817
—
—
0
10
93
914
10
93
75
733
11
98
48
444
No procedures
SPAT1301 [2001700402]
2.2e-01
—
—
—
—
—
4.3e-01
cases:11.83%
controls:9.68%
—
—
—
—
—
—
—
—
—
—
cases:13.56%
controls:9.23%
11
90
82
840
—
—
—
—
—
8
50
51
492
Cutaneous abscess, furuncle and carbuncle of trunk
L02.2 [45586751]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
93
924
—
—
—
—
—
—
Vaginal symptom/complaint other
X15 [2002001300]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
0
5
59
537
Body mass index
60621009 [4245997]
-6.6e-01
—
-1.0e+50
—
—
—
1.0e+50
cases:13.98%
controls:23.98%
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
cases:15.25%
controls:0.00%
13
223
80
707
—
0
5
93
925
—
—
—
9
0
50
542
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2.2e-01
2.9e-01
2.6e-01
—
1.8e-01
3.1e-01
-1.8e-02
cases:62.37%
controls:56.99%
cases:49.46%
controls:42.37%
cases:10.75%
controls:8.49%
—
—
cases:9.68%
controls:8.23%
cases:49.41%
controls:41.77%
cases:61.02%
controls:61.44%
58
530
35
400
46
394
47
536
10
79
83
851
—
9
76
84
848
42
345
43
481
36
333
23
209
Breast cancer
115 [2001600115]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.11%
—
—
—
—
—
—
0
6
59
536
Extensive body CT
JN4BD [2001310899]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
—
—
—
—
—
0
8
93
922
—
—
—
—
—
Prostate Pathology biopsy report
66117-3 [40768800]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
93
923
—
—
—
—
—
—
Feeling anxious/nervous/tense
P01 [2002000798]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
cases:0.00%
controls:1.48%
—
—
—
—
—
0
6
85
820
0
8
59
534
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
LC2BE [2001306544]
—
1.9e+00
—
—
—
—
—
—
—
cases:5.38%
controls:0.86%
—
—
—
—
—
—
—
—
—
—
—
5
8
88
922
—
—
—
—
—
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
4.2e-01
5.5e-02
—
—
-1.0e+50
6.6e-01
5.1e-01
cases:23.66%
controls:16.88%
cases:6.45%
controls:6.13%
—
—
—
—
cases:0.00%
controls:0.76%
cases:12.94%
controls:7.14%
cases:23.73%
controls:15.68%
22
157
71
773
6
57
87
873
—
—
0
7
93
917
11
59
74
767
14
85
45
457
exenatide; parenteral
A10BJ01 [1123633]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
93
924
—
—
—
—
—
—
calcium carbonate; oral
A12AA04 [21600863]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
cases:0.00%
controls:0.92%
—
—
—
—
—
0
5
85
821
0
5
59
537
CD3 cells/Lymphocytes in Blood
90304-7 [1175426]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
—
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
Epistaxis
R04.0 [45606791]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
0
5
59
537
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
—
—
—
—
—
—
2.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.47%
controls:7.01%
—
—
—
—
—
—
5
38
54
504
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
4.0e-01
6.9e-02
-1.0e+50
—
1.3e+00
4.4e-01
1.3e-01
cases:23.66%
controls:17.20%
cases:10.75%
controls:10.11%
cases:0.00%
controls:1.08%
—
—
cases:5.38%
controls:1.52%
cases:12.94%
controls:8.72%
cases:20.34%
controls:18.27%
22
160
71
770
10
94
83
836
0
10
93
920
—
5
14
88
910
11
72
74
754
12
99
47
443
citalopram; oral, parenteral
N06AB04 [21604712]
—
—
-1.0e+50
—
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
cases:0.00%
controls:0.54%
cases:0.00%
controls:2.30%
—
—
—
—
0
6
93
924
—
0
5
93
919
0
19
85
807
—
itraconazole; oral, parenteral
J02AC02 [21603081]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.08%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.29%
0
10
93
920
—
—
—
—
—
0
7
59
535
Metatarsalgia
M77.4 [45601544]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
93
924
—
—
—
—
—
—
Erythropoietin (EPO) [Units/volume] in Serum or Plasma
15061-5 [3024172]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
93
923
—
—
—
—
—
—
Atherosclerotic heart disease
I25.1 [45596196]
-2.7e-02
—
—
—
—
—
2.4e-01
cases:8.60%
controls:8.82%
—
—
—
—
—
—
—
—
—
—
cases:11.86%
controls:9.59%
8
82
85
848
—
—
—
—
—
7
52
52
490
Thyroglobulin [Mass/volume] in Serum or Plasma
3013-0 [3036535]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
—
Bacterial infection, unspecified
A49.9 [45590816]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
cases:0.00%
controls:0.97%
cases:0.00%
controls:2.40%
—
0
6
93
924
—
—
—
0
8
85
818
0
13
59
529
Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.57%
—
—
—
—
—
—
—
0
13
85
813
—
Spirometry for bronchospasm with prolonged evaluation after bronchodilator
113016006 [4010399]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
—
—
—
—
—
0
9
93
921
—
—
—
—
—
Simple adjuvant hormone therapy of malignancy
WB203 [2001310635]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
93
925
—
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
30
79
5.13
11.30
3.2
4.8
7.38
7.31
ph
1.34
22
52
18
36
5.94
6.62
2.2
3.5
—
—
—
0
0
55
322
2.73
5.29
5.6
4.2
—
—
—
0
0
63
443
2.31
3.48
4.6
6.3
0.17
0.18
e9/l
0.19
54
381
65
465
2.32
3.42
5.1
7.2
1.23
1.21
mmol/l
2.43
57
397
57
387
2.22
3.40
4.3
6.6
8.73
9.19
%
0.64
51
368
61
432
2.20
3.19
4.7
6.2
0.04
0.04
e9/l
0.15
52
364
59
413
2.17
3.17
4.8
6.6
1.24
1.21
mmol/l
2.46
50
383
56
386
2.13
3.11
4.3
6.5
0.65
0.67
%
0.12
50
364
56
388
2.11
3.05
4.3
6.5
2.23
2.71
%
1.05
50
367
59
417
2.13
3.05
2.3
2.2
87.56
96.58
pmol/l
0.61
25
201
57
399
2.11
3.00
4.2
6.5
24.81
25.58
%
0.18
51
380
60
430
2.11
2.95
4.6
6.2
0.63
0.60
e9/l
0.48
51
366
56
393
2.07
2.89
4.0
6.3
58.63
59.06
%
0.09
51
376
60
441
2.02
2.62
4.7
6.2
1.87
1.73
e9/l
0.58
53
387
42
280
1.91
2.38
2.5
2.6
—
—
—
0
0
84
732
2.52
2.19
6.0
5.4
2.06
1.96
mu/l
0.31
71
653
6
17
3.70
1.87
2.2
1.9
—
2.78
—
0
7
87
783
2.72
1.85
18.3
17.6
—
—
—
0
0
42
300
1.73
1.78
3.4
6.0
—
—
—
0
0
0
46
0.00
1.76
0.0
3.7
—
36.94
—
0
46
84
746
2.30
1.76
5.8
5.5
1.54
1.47
mmol/l
0.57
69
671
86
770
2.55
1.76
18.6
19.5
21.28
24.50
mg/l
0.57
80
666
16
273
0.50
1.74
5.5
6.9
—
—
—
0
0
10
41
2.61
1.70
1.9
2.6
—
0.00
estimate
—
0
14
82
720
2.17
1.63
4.8
4.6
1.20
1.26
mmol/l
0.36
64
644
86
778
2.40
1.62
6.4
6.4
2.55
2.56
mmol/l
0.02
70
700
84
752
2.21
1.62
5.7
5.5
4.52
4.49
mmol/l
0.10
68
680
40
288
1.68
1.62
2.6
2.4
70.25
56.43
u/l
1.49
35
264
60
482
1.69
1.59
5.6
10.5
4.46
4.38
e9/l
0.10
52
427
5
15
3.46
1.54
1.0
1.1
—
—
—
0
0
75
644
1.85
1.53
8.0
8.6
82.12
82.46
u/l
0.02
69
603
13
67
2.09
1.47
1.1
1.2
—
—
—
0
0
24
155
1.74
1.41
1.4
1.3
58.40
31.98
iu/ml
—
5
46
17
269
0.55
1.40
4.8
3.9
—
—
—
0
0
41
306
1.61
1.40
5.0
4.1
13.68
11.46
mg/mmol
0.07
25
186
40
297
1.61
1.40
4.4
3.2
49.59
64.93
mg/l
0.17
24
188
33
234
1.64
1.38
2.3
3.1
328.93
353.82
umol/l
0.84
27
193
9
42
2.26
1.38
1.3
1.4
—
—
—
0
0
50
393
1.59
1.37
2.5
2.9
—
—
estimate
—
0
0
39
293
1.57
1.27
2.0
1.8
21.70
22.08
nmol/l
0.05
27
233
0
34
0.00
1.18
0.0
3.0
—
3.94
—
0
34
83
754
1.94
1.15
6.4
5.8
6.04
6.05
mmol/l
0.05
69
674
48
385
1.51
1.13
4.6
4.4
31.50
47.40
ng/l
0.74
35
301
82
743
1.88
1.13
8.4
7.5
42.02
40.78
mmol/mol
0.30
71
682
29
383
0.65
1.11
6.6
13.8
0.00
0.00
e9/l
0.71
21
316
35
264
1.52
1.10
2.6
4.9
—
—
—
0
0
39
304
1.49
1.04
4.5
3.2
7.04
7.30
mmol/l
0.19
33
247
0
29
0.00
0.99
0.0
2.0
—
124.50
—
0
20
33
251
1.49
0.98
2.1
2.3
2.85
2.94
mg/l
0.10
25
219
26
342
0.67
0.94
5.1
4.6
12.98
89.40
e6/l
2.06
21
242
26
192
1.49
0.88
1.6
1.8
901.48
1269.39
nmol/l
1.83
18
142
0
26
0.00
0.80
0.0
1.7
—
—
—
0
0
9
141
0.60
0.77
4.4
7.4
105.89
104.35
mmol/l
—
9
141
13
84
1.64
0.77
2.6
2.8
0.20
0.22
g/l
0.46
13
76
7
40
1.81
0.73
1.4
1.2
—
—
—
0
0
50
434
1.33
0.64
21.9
16.7
1.30
1.30
inr
0.01
44
367
67
610
1.35
0.59
4.3
4.2
15.59
15.10
pmol/l
0.90
55
540
54
598
0.77
0.55
23.7
26.0
331.19
330.87
g/l
0.08
54
598
43
379
1.25
0.44
2.5
3.0
131.51
129.66
ug/l
0.02
36
348
10
70
1.48
0.44
5.0
3.4
—
—
—
0
0
0
15
0.00
0.41
0.0
3.1
—
31.40
—
0
15
10
71
1.46
0.41
1.4
1.8
—
—
—
0
0
0
18
0.00
0.40
0.0
1.6
—
—
—
0
0
0
18
0.00
0.40
0.0
3.6
—
—
—
0
0
0
19
0.00
0.39
0.0
1.4
—
61.84
—
0
19
0
19
0.00
0.39
0.0
2.8
—
54.84
—
0
19
9
68
1.36
0.39
3.0
2.3
9.36
9.95
g/l
—
9
58
14
177
0.75
0.37
4.1
3.1
0.57
0.81
ug/l
—
6
113
25
214
1.23
0.32
2.0
1.9
319.90
468.92
pmol/l
3.25
20
175
13
102
1.32
0.32
1.6
1.6
—
—
—
0
0
8
65
1.25
0.28
1.5
3.1
—
—
—
0
0
13
105
1.28
0.26
1.1
1.3
—
—
—
0
0
30
334
0.85
0.25
2.4
2.3
—
—
—
0
0
7
91
0.75
0.24
1.1
1.6
—
—
—
0
0
5
38
1.33
0.23
2.0
2.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.9
—
434.60
—
0
5
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.9
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.8
—
8.53
—
0
10
0
12
0.00
0.21
0.0
1.5
—
5.15
—
0
12
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.2
—
—
—
0
0
26
287
0.87
0.19
3.6
3.8
—
—
—
0
0
5
68
0.72
0.17
1.0
1.3
—
—
—
0
0
7
87
0.79
0.15
1.3
1.4
—
—
—
0
0
18
201
0.87
0.15
4.8
4.4
1.01
1.02
kg/l
0.58
12
127
12
106
1.15
0.10
1.2
1.5
—
—
—
0
0
33
312
1.09
0.10
2.0
3.4
2.40
2.35
mmol/l
1.16
22
281
6
71
0.83
0.08
2.2
1.6
—
—
—
0
0
40
414
0.94
0.06
3.6
4.6
36.43
34.74
g/l
0.88
35
389
14
132
1.07
0.03
1.1
1.3
—
—
—
0
0
18
172
1.06
0.02
1.3
1.5
2.27
2.97
g/l
0.70
11
94
31
303
1.03
0.01
1.6
2.0
1.19
1.34
mmol/l
0.77
25
249
12
118
1.02
0.00
3.8
7.5
-2.72
1.01
mmol/l
—
6
99
12
117
1.03
0.00
3.9
7.6
7.43
7.42
ph
—
6
67
18
177
1.02
0.00
5.3
4.9
—
—
—
0
0
22
215
1.03
0.00
1.3
1.4
—
—
—
0
0
13
125
1.05
0.00
1.3
2.2
—
—
—
0
0
11
106
1.04
0.00
1.5
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
4.4
—
78.70
—
0
5
6
60
1.00
-0.00
1.5
2.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.1
—
17.14
—
0
7
0
7
0.00
-0.00
0.0
1.4
—
32.97
—
0
7
0
8
0.00
-0.00
0.0
3.4
—
0.75
—
0
8
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
9
99
0.90
-0.00
1.2
1.4
—
—
—
0
0
38
380
1.00
-0.00
3.9
3.9
5.83
6.25
ph
1.69
21
209
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
14
140
1.00
-0.00
1.4
2.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.8
—
254.67
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
58
0.85
-0.00
3.6
2.7
1.63
1.34
g/l
—
5
52
0
7
0.00
-0.00
0.0
1.0
—
295.43
—
0
7
5
51
0.98
-0.00
1.8
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
3.1
—
5.01
—
0
7

Mortality – FinRegistry

↥

Association

Association between endpoint H7_POSTOPEYENAS and mortality.

Females

Parameter HR [95% CI] p-value
H7_POSTOPEYENAS 1.186 [0.87, 1.61] 0.277
Birth year 0.998 [0.99, 1.01] 0.592

During the follow-up period (1.1.1998 — 31.12.2019), 77 out of 221 females with H7_POSTOPEYENAS died.

Males

Parameter HR [95% CI] p-value
H7_POSTOPEYENAS 1.221 [0.89, 1.68] 0.222
Birth year 0.987 [0.98, 1.0] 0.009

During the follow-up period (1.1.1998 — 31.12.2019), 87 out of 207 males with H7_POSTOPEYENAS died.

Mortality risk

Mortality risk for people of age

years, who have H7_POSTOPEYENAS.

N-year risk Females Males
1 0.158% 0.267%
5 0.729% 1.541%
10 1.938% 3.612%
15 3.787% 6.642%
20 6.666% 11.455%

Relationships between endpoints

↥

Index endpoint: H7_POSTOPEYENAS – Other and unspecified postprocedural disorders of eye and adnexa

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data